fr   en
Clinical Studies
Phase :    
Announcement :   
Select a Pharma :
Select a product :
Select a disease :
Choose date:
[<<]      «      8   |   9   |   10   |   11   |   12   |   13   |   14   |   15   |   16   |   17   |   18      »      [57]
Date Phase Anouncement Biotech Pharma Product Disease Country Other
2009-11-06 II Launch Novexel (France)   NXL103 (flopristin/linopristin) acute bacterial skin and skin structure infections USA and Central America See details
2009-11-04 IIa Result Paion (Germany)   CNS 7056 (water-soluble, short-acting sedative acting on GABAa receptors in the brain) sedation USA See details
2009-11-04 I Launch Transgene (France)   TG4023 (MVA-FCU1), The product is based on a prodrug approach and involves insertion in vaccinal MVA vector of the FCU1 gene, a chimeric gene that combines the two enzymatic activities involved in transformation of 5-FC (5-fluorocytosine) to 5-FU (5-fluorouracil). TG4023 has a unique mechanism of action that converts a non-cytotoxic pro-drug, 5-FC, into 5-FU, a classic chemotherapeutic agent. The aim in this case is to increase the efficacy of chemotherapy while reducing its systemic toxicity through intratumoral injection of TG4023 in combination with the 5-FU precursor. hepatocellular carcinoma France See details
2009-11-02 I Launch Noxxon pharma (Germany)   NOX-A12 (hematopoietic stem cell mobilizing Spiegelmer®) this Spiegelmer® binds and neutralizes the chemokine Stromal Cell-Derived Factor-1 (SDF-1, also known as CXCL12), a key regulatory element in the homing and retention of HSCs in the bone marrow. NOX-A12 mobilizes hematopoietic stem cells from the bone marrow by disrupting the SDF-1 gradient that normally attracts them to their niches. autologous stem cell transplantation Germany See details
2009-11-02 III Result Human Genome Sciences (USA) GSK (UK) Benlysta® (belimumab - BLyS-specific inhibitor) It is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006. systemic lupus erythematosus (SLE) 19 countries, primarily in North America and Europe See details
2009-10-30 I Launch   Lundbeck (Denmark) Lu 02-750 (dopaminergic agent acting on brain areas affected in Parkinson's disease) This product has been discovered in close collaboration with Professor Håkan Wikström, Groningen University and Axon Biochemicals. Parkinson's disease   See details
2009-10-29 III Result   Roche (Switzerland) Ipsen (France) taspoglutide (glucagon-like-peptide-1 (GLP-1) analogue) Roche exercised its licensing option for taspoglutide from Ipsen in 2006 and acquired exclusive worldwide rights to develop and market taspoglutide, except in Japan where these rights are shared with Teijin and in France where Ipsen retained co-marketing rights. type 2 diabetes   See details
2009-10-23 III Launch Onyx Pharmaceuticals (USA) Bayer HealthCare (Germany) Nexavar® (sorafenib) radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer USA, Europe, Asia, Japan See details
2009-10-21 I Result Crucell (The Netherlands)   HIV vaccine using rAd26 (recombinant adenovirus serotype 26) vector The rAd26 vector is specifically designed to avoid the pre-existing immunity to the more commonly used adenovirus serotype 5 (Ad5). HIV/Aids USA See details
2009-10-20 I Result Affiris (Germany)   Alzheimer's vaccines AD01 and AD02 Alzheimer's disease Austria See details
2009-10-20 II Launch Action Pharma (Denmark)   AP214, organ protection in patients undergoing cardiac surgery Denmark See details
2009-10-19 I Launch Endotis Pharma (France)   EP217609 (synthetic parenteral neutralizable anticoagulant) and its specific antidote avidin. EP217609 has a dual mode of action combining the properties of an indirect factor Xa inhibitor and a direct thrombin inhibitor. In addition, EP217609 can be neutralized within a few minutes after administration of avidin. extracorporeal circulation in cardiac surgery,percutaneous coronary intervention in acute coronary syndromes   See details
2009-10-19 I Launch CellAct Pharma (Germany)   CAP7.1 (topoisomerase II inhibitor - prodrug of etoposide) advanced cancer Germany See details
2009-10-19 I-IIa Launch Cytheris (France)   CYT107 (recombinant glycosylated interleukin-7/IL-7) idiopathic CD4 lymphocytopenia (rare, orphan disease characterized by abnormally low CD4 T cell counts without evidence of human immunodeficiency virus (HIV-1 or HIV-2) infection) USA See details
2009-10-15 II Result Cytos Biotechnology (Switzerland) Novartis (Switzerland) nicotine vaccine NIC002 (therapeutic vaccine nicotine addiction   See details
[<<]      «      8   |   9   |   10   |   11   |   12   |   13   |   14   |   15   |   16   |   17   |   18      »      [57]